




ITEA 3 PARTNER Project

D1.2: Report on the Current State Patient Journey and Workflow

Lead beneficiary:	AMC
WP. no, title and activity type	WP1: End User & Clinical Requirements
Contributing Task (s)	Task 1.2: Current State Patient Journey and Workflow
Dissemination level	CO-confidential
Delivery date	M12
Status	Final





Authors List

Leading Authors (Editor)						
Name / Surname	Beneficiary Name (Short Name)	Contact email				
Martijn van Mourik	AMC	m.s.vanmourik@amc.nl				
Henk Marquering	AMC	h.a.marquering@amc.nl				
Co- Authors						
Name / Surname	Beneficiary Name (Short Name)	Contact email				
Kendall Ho	UBC	kendall.ho@ubc.ca				
HyungChul Rah	CNU	rah.remnant@gmail.com				
Annelinde Veen	Siemens	annelinde.veen@siemens- healthineers.com				
Joseph Yang	iClinic	jyang@iclinicemr.com				



Page 3 of 32

Executive Summary

In this document the current workflow and clinical situation of three different use cases are described which are a) Transcatheter Aortic Valve Implantation for aortic valve stenosis, b) Heart failure acute and non-acute and c) Cardiac rehabilitation. Three different clinical partners (Amsterdam UMC, Vancouver General Hospital and Chungbuk National University Hospital) have 3 different use cases with an overlap in collaborative workflow management, information transfer and shared decision making. All of these workflows serve as an example how care is currently organized and this deliverable serves as a blueprint for the next steps in identifying painpoints and bottlenecks in the current care organization.






Table of contents

ΕX	cecutive	Summary	3
Та	able of c	ontents	4
	1. D1	.2 Current State Patient Journey and Workflow	6
	Use cas	se 1: Transcatheter aortic valve implantation (TAVI)	6
	1.1.	Introduction	6
	1.2.	TAVI workflow at the AMC	7
	1.3.	Quality standards for the TAVI clinical pathway	9
	1.4.	Overview current hospital Imaging data Cardiology	10
	1.5.	Decision making based on medical Imaging	11
	1.6.	Clinical decision making questions	13
	Decisio	n making for TAVI – overview steps	13
	Decisio	n moment 1: Primary care	14
	Decisio	n moment 2: (referring) Cardiologist	14
	Decisio	n moment 3: Heartteam preparation	18
	Decisio	n moment 4: Heart Team discussion	18
	Decisio	n moment 5: THI team (Transcatheter Valve Team) preparation	20
	Decisio	n moment 6: THI team discussion	21
	Decisio	n moment 7: Procedure	23
	Decisio	n moment 8: Discharge	24
	Decisio	n moment 9: Follow-up/monitoring	25
	2. Us	e case 2: Heart failure (exacerbation)	27
	3. Us	e case 3: Cardiac Rehabilitation	31
	3.1.	Introduction	31
	3.2.	Aim and Expected results	31
	3.3.	Participants and Data collection	31
	3 4	Flowchart example (see supplement for full version)	32



Page 5 of 32

List of abbreviations and acronyms

AMC	Academic Medical Center (Dutch Hospital)
Amsterdam UMC	Amsterdam University Medical Centers
GP	General Practitioner (Family Doctor)
TAVI	Transcatheter Aortic Valve Implantation (synonym of TAVR)
UBC	University of British Columbia
VGH	Vancouver General Hospital
CBNU	Chungbuk National University
TAVR	Transcatheter Aortic Valve Replacement (synonym of TAVI)
AoS	Aortic Valve Stenosis
MI	Myocardial Infarction
EMR	Electronic Medical Record
MDT	Multidisciplinary Team Meeting

Page 6 of 32

1. D1.2 Current State Patient Journey and Workflow

Heart failure is the central theme of the patient journey and clinical use cases. In the PARTNER project three use cases. Each of the use cases has some overlap, but cover however a complete trajectory of a different disease state. The uses cases have in common that they all involve multidisciplinary collaborative decision making within cardiology department and beyond and data driven care is provided using both in-hospital as data acquired at an outpatient or home situation.

The three use cases are:

- 1) Transcatheter Aortic Valve Implantation [Treatment]
- 2) Heart failure, exacerbation/acute phase [Acute care]
- 3) Cardiac rehabilitation after myocardial infarction/chronic heart failure [Chronic/Rehabilitation care]

In each case 4 different phases can be identified:

Phase 1 - Monitoring:

In which a patient is usually in a home situation and has a chronic, but sometimes undetected underlying disease. A patient can be monitored to detect disease progression

Phase 2 - Admission, tests, diagnosis:

In this phase a patient is getting to a healthcare professional (acute phase) or is often referred to a specialized care center (TAVI case and chronic heart failure). The disease is detected, diagnosed and additional tests might be done in order to select the appropriate treatment option(s).

Phase 3 - Treatment:

A patient is admitted for (acute) treatment of the disease. Immediate rehabilitation will start directly after the procedure in an inpatient setting.

Phase 4 - Discharge and rehabilitation:

After immediate rehabilitation the more long term rehabilitation takes place after hospital discharge in an outpatient and patient home setting.

Use case 1: Transcatheter aortic valve implantation (TAVI)

1.1. Introduction

For a good understanding of the TAVI workflow all Dutch partners have visited clinical partner AMC. Martijn van Mourik invited all partners for two different sessions:

1. TAVI Multidisciplinary Team Meeting (MDT): in the team meeting an interventional-cardiologist, cardiothoracic surgeon, cardio-radiologist, geriatrician, nurse practitioner and others involved in the TAVI process make a decision if a TAVI procedure is indicated for a patient and if yes, how the procedure should be performed. Data from the referring physician such as the medical history and current signs, together with additionally acquired imaging (computed tomography angiography, coronary angiography and echocardiography) and other tests such as the electrocardiogram and lung function testing, are used to make decisions and form a complete overview of the patient.





Page 7 of 32

2. TAVI procedure: This minimally-invasive procedure takes about one to two hours and takes place at the (cardiac) catheterization laboratory or a hybrid operating room.

During the visit the industry partners were able to get an understanding of the process that takes place before a TAVI procedure is performed. A special focus was on the data is currently used in the decision making and how multidisciplinary team meetings take place.

1.2. TAVI workflow at the AMC

In the Netherlands referrals for the TAVI procedure are expected to come from cardiologists or other specialists in general hospitals. Referrals from the GP or primary care are not expected as patients with aortic valve stenosis are first seen by a general cardiologist. Alain Cribier performed the first TAVI¹ in humans in 2002 and since then there has been an incredible growth of this technique, supported by a substantial amount of research²,³.

In the past decade the TAVI treatment developed as a routine treatment of aortic valve disease (both aortic valve stenosis and aortic regurgitation) for those patients at intermediate-, high- or prohibitive risk for surgical aortic valve replacement.

General description of Aortic Valve Stenosis

Aortic valve stenosis (AoS) is a disease of the heart valve between the heart and the systematic circulation. It is in the Western population one of the most common heart valve diseases and the incidence is highly related with age. In the next years it is likely that the number of patients with AoS will increase due to an ageing society and better detection as the disease is also underdiagnosed.

Patients becoming symptomatic feel complaints of exercise related dyspnoea, chest pain, exhaustion, dizziness and sometimes syncope.

¹ Cribier A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation, 2002:106:3006-8

case description. Circulation. 2002;106:3006-8 ² Salinas P et al. State of the art of Aortic Valve Implantation: indications, outcomes, and controversies. EMJ Cardiol. 2015;3: 10-20.

^{10-20.}Salinas P et al. Transcatheter aortic valve implantation: Current status and future perspectives. World J Cardiol. 2011;3:177-



Page 8 of 32




Figure 1: Pre-TAVR considerations by the Heart Valve Team, adapted from https://doi.org/10.1016/j.jacc.2016.12.006, Otto et al 2017, JACC , vol 69, issue 10, p1313-1346.

of Patients with Valvular Heart Disease





Figure 2: Four phase description TAVI workflow.







When applying the four phases earlier described to the TAVI case:

Phase 1: chronic progressive phase of aortic AoS. Periodic monitoring is indicated in case of not severe enough aortic valve stenosis for treatment or symptoms not likely be caused by aortic valve stenosis.

Phase 2: TAVI screening: screening the severity of the AoS, possible treatment options and eligibility for TAVI

Phase 3: TAVI procedure: hospital admission for TAVI procedure and immediate post-procedural monitoring

Phase 4: Discharge and rehabilitation: after discharge rehabilitation and follow-up after the TAVI procedure

1.2.1. Collaborative decision making

The TAVI decision pathway is characterized by multidisciplinary decision making. Each patient is discussed in at least two different team meetings: 1) the Heart Team (consisting of at least an interventional cardiologist and cardiothoracic surgeon), and 2) the Transcatheter Heart Intervention – THI – team (consisting of an interventional cardiologist, cardiothoracic surgeon, cardioradiologist, specialized nurse and geriatrician). Figure 1 described the currently used guidelines.

The TAVI workflow is provided in a "swimming-lane"-flowchart of which an example can be found in Figure 4 and a full version as supplement to this document.

Communication from the AMC to the referral hospitals is done via Epic, using specialised modules for electronic transfer of letters like ZorgMail (encrypted e-mail)l or by regular mail.

1.3. Quality standards for the TAVI clinical pathway

Judicious selection of patients for TAVI is a complex process that requires thorough consideration. For a procedure to be deemed useful (as opposed to futile), it must offer a positive impact on life expectancy and quality of life. The best strategy for maximizing the utility of the procedure and minimizing its futility takes into account the patient's morbidity profile, the potential risks and anticipated benefits and the uncertain durability of the implants, in addition to economic considerations such as the burden placed on the health care system and the costs of the procedure⁴.

_

⁴ Abdelghani and Serruys, 2016



Page 10 of 32

1.4. Overview current hospital Imaging data Cardiology




Figure 3: Imaging data cardiology AMC. Agfa PACS II and Agfa VNA AMC are visible through the Electronic Medical Record by viewers.

Example flowchart/swimming lane TAVI process: (see supplement "S2-FlowChart-TAVI" for full version).





Figure 4: Flowchart/swimming lane, example of full version supplement.



1.5. Decision making based on medical Imaging



Abbreviations:

AS = aortic stenosis, CT = computed tomography, Echo = echocardiography, ECG = electrocardiogram, EF = ejection fraction, LV = left ventricular, LVEF = left ventricular ejection fraction, RV = right ventricular, LVEF = total ventricular

Additional evaluation including coronary angiography also is recommended as detailed in the Checklist shown in Table 2. This also includes the approach for patients with reduced renal function.

Figure 5: Imaging studies performed for TAVI for clinical decision making. Adapted from https://doi.org/10.1016/j.jacc.2016.12.006, Otto et al 2017, JACC, vol 69, issue 10, p1313-1346.

Page 12 of 32






Figure 6: TAVI decision pathway ACC: https://doi.org/10.1016/j.jacc.2016.12.006, Otto et al 2017, JACC, vol 69, issue 10, p1313-1346. This is taken from the latest American guidelines on TAVI treatment. Both the European (by the ESC: European Society of Cardiology) and the ACC/AHA (American College of Cardiology /American Heart Association).



ITEA Office

High Tech Campus 69 - 3 5656 AG Eindhoven The Netherlands T + 31 88 003 6136 E info@itea3.org W www.itea3.org

ITEA 3 is a EUREKA strategic ICT cluster programme

1.6. Clinical decision making questions

Decision making for TAVI – overview steps

The path from monitoring, diagnosis and intervention is interwoven with data collection, data interpretation to information in order to answer certain clinical questions in order to make decisions at decision making points. The different decision making points are indicated in the accompanied flowchart. A more detailed overview of all variables used at the different timepoints We addressed and defined the items as follows:

Clinical question

Used parameter(s): which parameters are used from a specific test or source?

Used interface: in which interface is the information displayed/visualized?

Source/data format: what is the source of the data and which format is used (eg. PACS/images)

Source/origin and storage: where is the data stored/retrieved from

Is and how is data transferred: if data needs to be transferred from external system to AMC, how is data transferred/converted?

Difficulty to retrieve information: how easy is it to find the data, especially in a categorized form or pre-defined datafield

Example

Zxampio						
Clinical question []	Used parameter(s) []	Used interface [EPIC]	Source/data format [eg CT-dicom]	Source/origin and storage [PACS origin referring center]	How is data transferred to AMC or N/A? [EVOCS]	Difficulty to retrieve information (easy/moderate/difficult)
What is the effective orifice area of the aortic valve	Aortic Valve Area (cm2)	ISCV	Echocardiagraphy images	Echo-pacs	EVOCS	moderate



Decision moment 1: Primary care

All referrals to a tertiary TAVI treatment center are done by a cardiologist.

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
Symptoms	Level of dyspnea					difficult
Medical history	Known diseases, previous treatments					difficult
Medication	Prescription					difficult

Decision moment 2: (referring) Cardiologist

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
Severity of the aortic valve stenosis?	Aortic Valve Area (cm²) Indexed Aortic Valve	GE echoweb / Philips IntelliSpace	Echocardiography + report	Referral letter	Electronically by EVOCS	Moderate (especially measurements often not used in standardized format)



Page 15 of 32

	Area	Cardiovascular				1 4 5 1 5 1 5
	AoV Pressure gradient (mmHg)				by Fax/regular mail	
Other valvular disease?	Mitral valve stenosis/regurgitation Tricuspid valve stenosis/regurgitation	GE echoweb / Philips IntelliSpace Cardiovascular	Echocardiography + report	Referral letter	Electronically by EVOCS or by Fax/regular mail	Moderate (especially measurements often not used in standardized format)
Overall heart function?	Left ventricular ejection fraction Wall motion Systolic Pulmonary Artery Pressure Ventricle and atrial	GE echoweb / Philips IntelliSpace Cardiovascular	Echocardiography + report	Referral letter	Electronically by EVOCS or by Fax/regular mail	Moderate (especially measurements often not used in standardized format)



WP1 Deliverable: D1.2 Page 16 of 32

						rage roor.
	dimensions					
Aortic valve stenosis symptoms?	Patient complaints: Description of complaints; focus on dyspnea (NYHA class), chest pain (CCS class), fatigue, syncope, dizziness	EPIC: scanned documents	Described symptoms	Referral letter	By Fax/regular mail/e-mail	Moderate
Are there other causes for complaints?	Pulmonary function testing Coronary Angiogram	EPIC: scanned documents Scanned documents/ images in IntelliSpace cardiovascular	Pulmonary function testing CAG	Referral letter / imaging	Fax/regular mail/e-mail Electronically by EVOCS or by Fax/regular mail and CD	Moderate
Relevant comorbidities to deny for surgical aortic valve repair?	Medical history: Extracardiac arteriopathy Poor mobility	EPIC: scanned documents	Medical history	Referral letter	By Fax/regular mail/e-mail	Easy



WP1 Deliverable: D1.2 Page 17 of 32

			1 4 5 1 7 0 1 3 2
Previous cardiac surgery			
Chest radiation			
Chronic pulmonary pulmonary disease (also from pulm test)			
Diabetes Mellitus			
Left ventricular function			
Pulmonary hypertension			
Porcelain aorta			
Frailty			
Severe liver disease			



Page 18 of 32

What are the patients preferences?	Patient and family input	EPIC: scanned documents	Medical history/anamnesis	Referral letter	By Fax/regular mail/e-mail	Moderate

Decision moment 3: Heartteam preparation

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
Is all data complete for Heartteam discussion for Aortic Valve Stenosis?	Referral letter Ultrasonography CAG	ISCV/EchoWeb	Scanned documents	N/A	Letters: fax, email, post Images: CD or EVOCS	moderate

Decision moment 4: Heart Team discussion

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to	Difficulty to retrieve information
					AMC or N/A?	(easy/moderate/difficult)



WP1 Deliverable: D1.2 Page 19 of 32

						1 4 5 6 1 7 6 1 .
What is the severity of aortic valve stenosis?	Aortic Valve Area (cm²) Indexed Aortic Valve Area AoV Pressure gradient (mmHg)	EPIC or ISCV	Referral letter	Scanned documents in EPIC or original images in IntelliSpace Cardiovascular or Echoweb	Letters: fax, email, post Images: CD or EVOCS	moderate
Is the patient symptomatic?	Description of complaints; focus on dyspnea (NYHA class), chest pain (CCS class), fatigue, syncope, dizziness Exercise intolerance	EPIC	Referral letter	Scanned documents in EPIC	: fax, email, post	moderate
Relevant comorbidities to deny for	Medical history	EPIC	Scanned documents/ Referral letter	Scanned documents	E-mail/Fax/Post	moderate



Page 20 of 32

						1 480 20 01 02
surgical aortic valve repair?	Pulmonary functioning testing	EPIC	Scanned documents/ test report		E-mail/Fax/Post	easy
What are the patients preferences?	Referral letter	EPIC	Scanned documents/ Referral letter	Referring hospital EMR	E-mail/Fax/Post	moderate
Are extra tests necessary to make decision regarding TAVI?	Major comorbidities needing exploration: malignancies, anemia	EPIC	MDT note	Referring hospital EMR	E-mail/Fax/Post	moderate

Decision moment 5: THI team (Transcatheter Valve Team) preparation

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
----------------------	----------------------	----------------	-----------------------	---------------------------	--	--



WP1 Deliverable: D1.2 Page 21 of 32

Is all data complete for THI-team discussion for TAVI?	-	-	-	-	-	-
Were all open items from Heartteam discussion solved?	Heart Team report	EPIC	Report of Heartteam	EPIC	N/A	Easy (but mostly free text)

Decision moment 6: THI team discussion

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
What is the severity of aortic valve stenosis?	Aortic Valve Area, Aortic Valve Pressure gradient	EPIC	Ultrasonography images	IntelliSpace / GE- EchoPAC	Already imported Already imported	moderate
Is the patient symptomatic?	Medical history	EPIC	Clinical note	EPIC or referral	N/A	moderate



WP1 Deliverable: D1.2 Page 22 of 32

Baseline ECG?	Rhythm Conduction times (QRS, PR-interval, ST) Heart axis Abnormalities	EPIC	ECG	EPIC / Muse	N/A	easy
Relevant comorbidities to deny for surgical aortic valve repair?	Medical history Pulmonary functioning testing	EPIC	Scanned documents/ Referral letter Scanned documents/ test report	Scanned documents, referring hospital EMR	Already imported Already imported	Moderate
What are the patients preferences?	Referral letter and medical history	EPIC	Scanned documents/ Referral letter And Clinical note	EPIC	E-mail/Fax/Post	moderate
Are extra tests necessary to make decision regarding TAVI?	Comorbidities needing exploration: malignancies, anemia, other	EPIC	MDT meeting note	EPIC	N/A	moderate



WP1 Deliverable: D1.2 Page 23 of 32

TAVI prosthesis valve size?	CT-scan: Annulus area	EPIC	Report in EPIC / Images from PACS	PACS	N/A	easy
Femoral or non- femoral approach?	CT-scan: diameters of peripheral arteries and arterial trajectory to aortic valve	EPIC	Report in EPIC / Images from PACS	PACS	N/A	easy

Decision moment 7: Procedure

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
Predilation necessary?	Aortic valve calcification	EPIC	СТ	PACS	N/A	Easy
Postdilation necessary?	Aortic valve regurgitation	Xcelera imaging system	Philips X-ray (Allura clarity)	Xcelera/IntelliSpace Cardiovscular	N/A	easy



WP1 Deliverable: D1.2 Page 24 of 32

Can the	Peri-	MacLab	MacLab	N/A	easy
temporary	procedural				
pacemaker wire	ECG				
be removed?					

Decision moment 8: Discharge

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
No conduction disturbances?	QRS duratino	EPIC/Muse	ECG	Muse	N/A	easy
Bloodwork ok?	Complete blood work	EPIC	Lab data	Labtrain	N/A	easy
Access site free from complications	Physical examination	EPIC	Clinical note	EPIC	N/A	moderate
Discharge medication	Medication prescription	EPIC	Clinical note	EPIC	N/A	Easy

WP1 Deliverable: D1.2 Page 25 of 32

overview			

Decision moment 9: Follow-up/monitoring

Clinical question	Used parameter(s)	Used interface	Source/data format	Source/origin and storage	How is data transferred to AMC or N/A?	Difficulty to retrieve information (easy/moderate/difficult)
Symptoms	Description of complaints; focus on dyspnea (NYHA class), chest pain (CCS class), fatigue, syncope, dizziness Exercise intolerance	EPIC or	Clinical note or outpatient clinic follow-up letter from referring hospital	Scanned documents in EPIC or original	E-mail/Fax/Post	Moderate
Quality of life	SF-36, EQ5D		Clinical note or	Scanned documents	E-mail/Fax/Post	Moderate



Page	26	of	32
------	----	----	----

	questionnaires		outpatient clinic follow-up letter from referring hospital	in EPIC or original		
Antithrombotic therapy?	Medication prescription		Clinical note or outpatient clinic follow-up letter from referring hospital	Scanned documents in EPIC or original	E-mail/Fax/Post	Moderate
Bioprosthetic Valve function?	Aortic Valve Area (cm²) Indexed Aortic Valve Area AoV Pressure gradient (mmHg)	EPIC or ISCV	Referral letter	Scanned documents in EPIC or original images in IntelliSpace Cardiovascular or Echoweb	Letters: fax, email, post Images: CD or EVOCS	moderate
Conduction disturbances?						
Stroke?						



ITEA 3 is a EUREKA strategic ICT cluster programme

2. Use case 2: Heart failure (exacerbation)

Monitoring Stage*	Motivation	Data needs of health professionals	Data needs of patients/caregivers
Heart Failure Stable Status	Community/home based monitoring to maintain wellness and patient optimization of self-management	Routine, episodic tracking of physiologic metrics, patient education	Awareness of physiologic metrics and self-monitoring for normality
Step-up monitoring and therapy adjustment	Community/home based, increased monitoring to prevent further deterioration, and adjustment of therapies to re- establish stability	More intense monitoring periods (e.g. daily, or even multiple times per day) of physiologic metrics, and adjustment of medications to ensure reversal of clinical course back towards stability or detection of deterioration requiring further stepping up of therapy or emergency admission	Partnership with health professionals to closely watch physiologic metrics, and adhere to increased therapies to watch of frequency of abnormalities and correlation of symptoms to try to re-establish stabilization or if worsen, seek further help or present self to emergency if danger level reached
Intense monitoring and acute therapy	Emergency based, intense monitoring to acutely correct life-threatening conditions to re-establish safe status of patient	Intense monitoring (e.g. hourly or even minute-by-minute) of physiologic metrics, and escalation or addition of medications to prevent life threatening status and de-escalate unstable clinical status	Report symptoms to health professionals and correlate with physiologic metrics so health professionals can support patients through this unstable and potentially life threatening stage
Hospital monitoring and therapy	Hospital based (ward or intense care unit) monitoring to titrate acute therapies to stabilize patients and re-achieve safe and non-life threatening health status	Intense (e.g. ICU) and gradually step down the frequency of monitoring (e.g. ward) when patients start to stabilize and recovering from life-threatening status, and titration of acutely prescribed medications to achieve therapeutic effects with minimum doses of medications or prevent side effects	Report symptoms to health professionals and correlate with physiologic metrics to health professionals can help tweak the medical therapies to achieve therapeutic goals without inadvertently increasing side effects or inducing adverse effects of therapy. Patients and caregivers can start selfmanagement to experience recovery and level of activities and sense of wellness for potential return to home for convalescence in partnership with health professionals.
Rehabilitation monitoring and therapeutic de-	Community/home based monitoring to ensure gradual recovery of patients to	Gradually decrease intensity of monitoring (e.g. daily and then decreasing to every other day) to ensure	Partnership with health professionals to self-monitor physiologic metrics and reporting of symptoms during





Page 28 of 32

escalation	their baseline status	continuity of stability, and also use this monitoring to guide gradual decrease in therapy back to patients' baseline medications or stoppage of some of them.	recovery, or any unexpected side effects from medicines. Ensure implementation of non-therapeutic approaches (e.g. reduce amount of fluid intake, increased gradual exercises) and partner with health professionals to ensure safe and effective rehabilitation.
Palliative monitoring and comfort therapy	Community/home based monitoring to ensure patient comfort	Infrequent monitoring or even withdrawal of monitoring when appropriate only to ensure patients remain comfortable, even if the physiologic metrics may continue to deteriorate.	Patients and caregivers report level of comfort (e.g. ensuring enough analgesics to reduce discomfort of shortness of breath) so health professionals can help adjust comfort care therapies to tailor to patient need.



Page 29 of 32




Figure 7: Workflow Heartfailure Exacerbation (full version supplemental S2a).



ITEA Office

High Tech Campus 69 - 3 5656 AG Eindhoven The Netherlands T + 31 88 003 6136 E info@itea3.org W www.itea3.org

ITEA 3 is a EUREKA strategic ICT cluster programme




Figure 8: Workflow heartfailure Vancouver General Hospital, swimming lane (full version supplemental S2b).



3. Use case 3: Cardiac Rehabilitation

3.1. Introduction

ITEA3

Cardiac rehabilitation of myocardial infarction may reduce recurrence of coronary artery diseases (CAD) by 15 - 20% and CAD mortality by 25 - 40%.

- Due to the concerns that exercise may be dangerous for CAD patients, doctors are reluctant to order or recommend exercise to CAD patients.
- However, monitored exercise, especially with EKG monitoring, may lower any risk during exercises.
- Obstacles that keep cardiac rehabilitation patients from participating at below 5%
- Obstacles include low recognition rate, far distance to hospitals with cardiac rehabilitation facilities (only 21 hospitals in Korea), no coverage by national health insurance, difficult transportation, lack of caregiver to bring patients to hospitals, etc.
- Low participation rate needs improvement.

3.2. Aim and Expected results

The aim is to provide patients who need cardiac rehabilitation with a solution for healthy life with well-managed cardiovascular risk factors.

- High-risk patients must be monitored in the hospital and low-risk patients should be encouraged to engage in exercises in the home or workplace.
- By using wearable devices, smartphone apps, and platform to integrated monitoring of patient's condition, patient's condition can be constantly monitored at their residency.

Bio-signals of patients are to be monitored within device and by caregivers, and evaluated at the time of hospital visits by physicians.

- Expected results
- Patient compliance to be improved by providing feedback from physicians to patients during their visits to hospitals
- Participation rate of cardiac rehabilitation to be improved from 5% up to 30%.
- CAD recurrence rate and CAD mortality to be reduced by 15-20% and by 25-40%, respectively.

3.3. Participants and Data collection

Participants

- Clinicians: physicians from interdisciplinary collaboration including rehabilitation medicine and cardiology
- Patient Caregivers: Caregivers or patient's family members who take care of patients at patient's residency



- Patients: recovering patients who were hospitalized or had coronary intervention or coronary artery bypass graft for acute coronary artery syndrome,

Data collection

- Wearable device for bio-signals of patients: passive monitoring of electrocardiogram for arrhythmia, blood pressure for low blood pressure, heart rate for exercise intensity, and step count for activity
- Smartphone apps: active data input by patients on rate of perceived exertion and on life style and diet

3.4. Flowchart example (see supplement for full version)




Figure 9: Flowchart workflow and swimminglane cardiac rehabilitation Chungbuk National University Hospital (full version supplement S3).